Infliximab Dosing for Ulcerative Colitis
For moderate-to-severe ulcerative colitis, administer infliximab 5 mg/kg intravenously at weeks 0,2, and 6 for induction, followed by 5 mg/kg every 8 weeks for maintenance. 1
Standard Dosing Regimen
Induction Phase
- 5 mg/kg IV at weeks 0,2, and 6 1
- This applies to both adults and pediatric patients ≥6 years old
- Clinical response typically assessed at week 8
Maintenance Phase
- 5 mg/kg IV every 8 weeks after completing induction 1
- Continue indefinitely for sustained remission
- Combination with thiopurines (azathioprine or mercaptopurine) is more effective than monotherapy and should be used for at least 6-12 months 2
Acute Severe Ulcerative Colitis (ASUC)
In hospitalized patients with steroid-refractory ASUC, use standard 5 mg/kg dosing initially. The evidence does not support routine use of intensified dosing (10 mg/kg or accelerated schedules) upfront 3, 4.
When to Consider Accelerated Dosing
If patients fail to respond adequately after 3-5 days:
- Administer an early repeat infusion (accelerated dosing) 5
- Particularly beneficial in patients with:
Critical caveat: Accelerated dosing should only occur after colorectal surgical review confirms colectomy is not immediately required 5. The 2024 PREDICT-UC trial found no significant difference between 10 mg/kg and 5 mg/kg initial dosing for day 7 clinical response (65% vs 61%, p=0.62) 4. However, patients with high infliximab clearance (≥0.62 L/day) may benefit from higher initial doses 6.
Monitoring in ASUC
- Day 3 serum infliximab level ≤57.9 μg/mL predicts colectomy risk (83% sensitivity, 97% negative predictive value) 6
- Consider therapeutic drug monitoring to guide dose intensification decisions
- Median time to response is 4 days; failure to respond by day 7 warrants surgical consultation 7
Efficacy Data
The ACT 1 and ACT 2 trials established infliximab's efficacy 8:
- Week 8 clinical response: 61-69% (vs 29-37% placebo)
- Week 54 clinical response: 44-45% (vs 20% placebo)
- Maintenance remission rates: Approximately 40% at 8-9 months 3, 9
In pediatric UC, 73.3% achieved week 8 response, with 28.6% overall remission at week 54 using every-8-week maintenance 10.
Loss of Response and Dose Escalation
Annual loss of response occurs in 10% of patients (higher at 13.6% in the first year) 11. When loss of response occurs:
- Consider dose escalation to 10 mg/kg every 8 weeks 1
- Alternatively, shorten interval to every 4-6 weeks (though this increases infection risk) 1
- Check infliximab trough levels and antibodies to guide decision
- Dose escalation regains clinical benefit in 72% of patients 11
Common Pitfalls
Delaying surgery in ASUC: Do not continue multiple infliximab doses if no response by day 7. Prolonged medical therapy before colectomy increases postoperative complications 5
Sequential rescue therapy: Avoid switching from infliximab to ciclosporin (or vice versa) in ASUC—this increases serious adverse events without clear benefit 5
Inadequate combination therapy: Failing to add thiopurines during induction reduces efficacy and increases immunogenicity 2, 5
Premature discontinuation: Patients who don't respond by week 14 are unlikely to benefit from continued dosing and should be considered for alternative therapy 1
Safety Considerations
Serious adverse events occur at similar rates to placebo in controlled trials 2, 8. However: